Loading...
Immunis Recognition: Immunis, Inc. has been named one of the “Top 25 Biotech & Life Sciences Companies for 2025” by The Healthcare Technology Report, highlighting its innovative stem cell-derived therapy, IMM01-STEM, aimed at combating age-related muscle atrophy.
Company Overview: As a clinical-stage biotech firm, Immunis focuses on developing biologics from stem cell secretome technology to address immune dysregulation and age-related diseases, positioning itself as a leader in patient-centered biotechnology.
